<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17492425</article-id><article-id pub-id-type="pmc">1914282</article-id><article-id pub-id-type="publisher-id">699</article-id><article-id pub-id-type="doi">10.1007/s00125-007-0699-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Beulens</surname><given-names>J. W. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Loon</surname><given-names>L. J. C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kok</surname><given-names>F. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pelsers</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bobbert</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spranger</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helander</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hendriks</surname><given-names>H. F. J.</given-names></name><address><phone>+31-30-6944928</phone><fax>+31-30-6944294</fax><email>henk.hendriks@tno.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>TNO Quality of Life, Business Unit Biosciences, Utrechtseweg 48, 3704 HE Zeist, P.O. Box 360, 3700 AJ Zeist, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Human Nutrition, Wageningen University, Wageningen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Movement Sciences, Maastricht University, Maastricht, The Netherlands </aff><aff id="Aff4"><label>4</label>Department of Clinical Nutrition, German Institute of Human Nutrition Postdam-Rehbruecke, Nuthetal, Germany </aff><aff id="Aff5"><label>5</label>Department of Endocrinology Diabetes and Nutrition, Charit&#x000e9;-University Medical School Berlin, Berlin, Germany </aff><aff id="Aff6"><label>6</label>Alcohol Laboratory, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>5</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2007</year></pub-date><volume>50</volume><issue>7</issue><fpage>1388</fpage><lpage>1392</lpage><history><date date-type="received"><day>26</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>2</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag 2007</copyright-statement></permissions><abstract><sec><title>Aims/hypothesis</title><p>The aim of this study was to investigate whether moderate alcohol consumption increases plasma high molecular weight (HMW) adiponectin and/or muscle oxidative capacity.</p></sec><sec><title>Materials and methods</title><p>Eleven lean (BMI 18&#x02013;25&#x000a0;kg/m<sup>2</sup>) and eight overweight (BMI &#x02265;27&#x000a0;kg/m<sup>2</sup>) men consumed 100&#x000a0;ml whisky (&#x0223c;32&#x000a0;g alcohol) or water daily for 4&#x000a0;weeks in a randomised, controlled, crossover trial. After each treatment period, muscle biopsies and fasting blood samples were collected.</p></sec><sec><title>Results</title><p>Adiponectin concentrations increased (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) by 12.5% after 4&#x000a0;weeks of moderate alcohol consumption. Moderate alcohol consumption tended to increase HMW adiponectin by 57% (<italic>p</italic>&#x02009;=&#x02009;0.07) and medium molecular weight adiponectin by 12.5% (<italic>p</italic>&#x02009;=&#x02009;0.07), but not low molecular weight (LMW) adiponectin. Skeletal muscle citrate synthase, cytochrome <italic>c</italic> oxidase and &#x003b2;-3-hydroxyacyl coenzyme A dehydrogenase (&#x003b2;-HAD) activity were not changed after moderate alcohol consumption, but an interaction between alcohol consumption and BMI was observed for cytochrome <italic>c</italic> oxidase (<italic>p</italic>&#x02009;=&#x02009;0.072) and citrate synthase (<italic>p</italic>&#x02009;=&#x02009;0.102) activity. Among lean men, moderate alcohol consumption tended to increase cytochrome <italic>c</italic> oxidase (<italic>p</italic>&#x02009;=&#x02009;0.08) and citrate synthase activity (<italic>p</italic>&#x02009;=&#x02009;0.12) by 23 and 26%, respectively, but not among overweight men. In particular, plasma HMW adiponectin correlated positively with activities of skeletal muscle citrate synthase (<italic>r</italic>&#x02009;=&#x02009;0.64, <italic>p</italic>&#x02009;=&#x02009;0.009), cytochrome <italic>c</italic> oxidase (<italic>p</italic>&#x02009;=&#x02009;0.59, <italic>p</italic>&#x02009;=&#x02009;0.009) and &#x003b2;-HAD (<italic>r</italic>&#x02009;=&#x02009;0.46, <italic>p</italic>&#x02009;=&#x02009;0.056), while such correlation was not present for LMW adiponectin. Whole-body insulin sensitivity and intramyocellular triacylglycerol content were not affected by moderate alcohol consumption.</p></sec><sec><title>Conclusions/interpretation</title><p>Moderate alcohol consumption increases adiponectin concentrations, and in particular HMW adiponectin. Concentrations of HMW adiponectin in particular were positively associated with skeletal muscle oxidative capacity.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Adiponectin</kwd><kwd>High molecular weight adiponectin</kwd><kwd>Insulin sensitivity</kwd><kwd>Intramyocellular triacylglycerols</kwd><kwd>Moderate alcohol consumption</kwd><kwd>Muscle oxidative capacity</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Moderate alcohol consumption is associated with a decreased risk of type 2 diabetes compared with abstention [<xref ref-type="bibr" rid="CR1">1</xref>], which could be explained by improved insulin sensitivity [<xref ref-type="bibr" rid="CR2">2</xref>]. The underlying mechanism for this is not clear, but several pathways may be involved. First, moderate alcohol consumption increases plasma adiponectin concentrations, which could precede changes in insulin sensitivity [<xref ref-type="bibr" rid="CR2">2</xref>]. Adiponectin improves insulin sensitivity by increasing muscle fat oxidation and/or decreasing intramyocellular triacylglycerols (IMTGs) [<xref ref-type="bibr" rid="CR3">3</xref>]. Adiponectin is present in plasma as a trimer, hexamer or high molecular weight (HMW) form, the latter possibly being the most relevant in the aetiology of insulin resistance [<xref ref-type="bibr" rid="CR4">4</xref>]. Second, moderate alcohol consumption acutely affects energy expenditure, diet-induced thermogenesis, lipolysis and lipid oxidation [<xref ref-type="bibr" rid="CR5">5</xref>]. These changes may result from acetate production from ethanol, which is converted to acetyl-CoA mainly in peripheral tissue such as muscle [<xref ref-type="bibr" rid="CR5">5</xref>]. Such acute changes could cumulatively affect oxidative capacity and insulin sensitivity. This is the first human study to investigate whether chronic moderate alcohol consumption affects plasma adiponectin oligomers and muscle oxidative capacity.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p>In a randomised, controlled, crossover trial, conducted at TNO Quality of Life, 19 healthy, moderate-drinking, lean (BMI 18&#x02013;25&#x000a0;kg/m<sup>2</sup>, <italic>n</italic>&#x02009;=&#x02009;11) and overweight (BMI &#x02265;27&#x000a0;kg/m<sup>2</sup>, <italic>n</italic>&#x02009;=&#x02009;8) men (aged 18&#x02013;40&#x000a0;years), consumed 100&#x000a0;ml whisky (32&#x000a0;g alcohol per day; Famous Grouse Scotch Whisky, 40% vol, Perth, Scotland) or mineral water (Spa Reine, Spa, Belgium) daily for 4&#x000a0;weeks. For the last 7&#x000a0;days of each treatment period the diet was fully controlled, and treatments were separated by a 2&#x000a0;day wash-out period. This sample size was sufficient to detect &#x0223c;15% difference of &#x003b2;-3-hydroxyacyl-CoA dehydrogenase (&#x003b2;-HAD) and citrate synthase activity in this crossover trial and correlation coefficients of 0.55 or higher with 80% power and accepting an alpha of 0.05. At the end of each treatment period, muscle biopsies from the vastus lateralis muscle were taken to assess &#x003b2;-HAD, cytochrome <italic>c</italic> oxidase and citrate synthase activity [<xref ref-type="bibr" rid="CR6">6</xref>], IMTG [<xref ref-type="bibr" rid="CR7">7</xref>] and succinate dehydrogenase activity [<xref ref-type="bibr" rid="CR8">8</xref>]. Fasting blood samples were collected and an OGTT was performed to calculate whole-body insulin sensitivity. Subjects gave written informed consent and the University Medical Center Utrecht Medical Ethics Committee approved the protocol. The study was conducted according to the Declaration of Helsinki (2000) and the International Conference on Harmonisation Guidelines for Good Clinical Practice. Data were analysed using the SAS statistical software package (SAS/STAT version 8, SAS Institute, Cary, NC, USA). Treatment effects were assessed by ANOVA, using general linear modelling, with BMI, period, treatment and treatment order included in the model. Two-sided <italic>p</italic> values below 0.05 were considered statistically significant.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>Compliance to treatments was good as assessed by measurements of urinary ethyl glucuronide every 5&#x000a0;days, showing one negative sample during the whisky-drinking and no positive samples during the water-drinking period. Another indication was the 11% increase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) of serum HDL-cholesterol after whisky compared with water consumption. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows results on insulin sensitivity, adiponectin and muscle enzyme activities. Insulin sensitivity was not changed after moderate alcohol consumption, but plasma adiponectin concentrations increased from 7.9&#x02009;&#x000b1;&#x02009;0.2&#x000a0;mg/l after water to 9.0&#x02009;&#x000b1;&#x02009;0.2&#x000a0;mg/l (means&#x000b1;SEM) after whisky consumption. Moderate alcohol consumption tended to increase HMW and medium molecular weight (MMW) adiponectin, but not low molecular weight (LMW) adiponectin. Differences in insulin sensitivity and adiponectin and its oligomers tended to be more pronounced among lean than overweight men (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Muscle oxidative capacity measured by &#x003b2;-HAD, cytochrome <italic>c</italic> oxidase and citrate synthase activity did not differ between treatments. A borderline significant interaction between treatment and BMI was observed for cytochrome <italic>c</italic> oxidase (<italic>p</italic>&#x02009;=&#x02009;0.072) and citrate synthase (<italic>p</italic>&#x02009;=&#x02009;0.102) activity. Moderate alcohol consumption tended to increase cytochrome <italic>c</italic> oxidase (+23.7%; 95% CI &#x02212;3.9 to +51.2%, <italic>p</italic>&#x02009;=&#x02009;0.08) and citrate synthase (+24.7%; 95% CI &#x02212;7.7 to +57.2%, <italic>p</italic>&#x02009;=&#x02009;0.11) activity among lean, but not overweight men (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Succinate dehydrogenase activity in mixed muscle fibres decreased (<italic>p</italic>&#x02009;=&#x02009;0.03) by 15% after moderate alcohol consumption. IMTGs did not differ, despite a 15&#x02013;20% difference between both treatments. These results were not different for lean and overweight men (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). After whisky consumption, HMW correlated positively with activities of citrate synthase (<italic>r</italic>&#x02009;=&#x02009;0.64, <italic>p</italic>&#x02009;=&#x02009;0.004), cytochrome <italic>c</italic> oxidase (<italic>r</italic>&#x02009;=&#x02009;0.59, <italic>p</italic>&#x02009;=&#x02009;0.009) and &#x003b2;-HAD (<italic>r</italic>&#x02009;=&#x02009;0.46, <italic>p</italic>&#x02009;=&#x02009;0.056). Activities of citrate synthase (<italic>r</italic>&#x02009;=&#x02009;0.44, <italic>p</italic>&#x02009;=&#x02009;0.07), cytochrome <italic>c</italic> oxidase (<italic>r</italic>&#x02009;=&#x02009;0.32, <italic>p</italic>&#x02009;=&#x02009;0.20) and &#x003b2;-HAD (<italic>r</italic>&#x02009;=&#x02009;0.44, <italic>p</italic>&#x02009;=&#x02009;0.07) also tended to correlate with MMW adiponectin, but not LMW adiponectin. A similar pattern was observed for correlations of adiponectin oligomers with HDL-cholesterol (HMW: <italic>r</italic>&#x02009;=&#x02009;0.55, <italic>p</italic>&#x02009;=&#x02009;0.014; MMW: <italic>r</italic>&#x02009;=&#x02009;0.55, <italic>p</italic>&#x02009;=&#x02009;0.014; LMW: <italic>r</italic>&#x02009;=&#x02009;0.21, <italic>p</italic>&#x02009;=&#x02009;0.38).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Insulin sensitivity index, adiponectin oligomer concentrations, HbA<sub>1c</sub> and enzyme activities after 4&#x000a0;weeks of consumption of whisky or mineral water in 19 lean or overweight men</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#x000a0;</th><th>Mineral water</th><th>Whisky</th><th>% Change</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Insulin sensitivity index<sup>a</sup></td><td>10.6&#x02009;&#x000b1;&#x02009;1.3</td><td>9.6&#x02009;&#x000b1;&#x02009;1.3</td><td>&#x02212;9.4</td><td>0.61</td></tr><tr><td>Adiponectin (mg/l)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.2</td><td>9.0&#x02009;&#x000b1;&#x02009;0.2</td><td>12.5</td><td>0.0008</td></tr><tr><td>&#x000a0;HMW</td><td>0.7&#x02009;&#x000b1;&#x02009;0.1</td><td>1.1&#x02009;&#x000b1;&#x02009;0.1</td><td>57.1 </td><td>0.074</td></tr><tr><td>&#x000a0;MMW</td><td>4.0&#x02009;&#x000b1;&#x02009;0.2</td><td>4.5&#x02009;&#x000b1;&#x02009;0.2</td><td>12.5</td><td>0.065</td></tr><tr><td>&#x000a0;LMW</td><td>3.2&#x02009;&#x000b1;&#x02009;0.3</td><td>3.5&#x02009;&#x000b1;&#x02009;0.3</td><td>9.4</td><td>0.442</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>4.9&#x02009;&#x000b1;&#x02009;0.02</td><td>4.8&#x02009;&#x000b1;&#x02009;0.02</td><td>&#x02212;2.0</td><td>0.023</td></tr><tr><td>Muscle &#x003b2;-HAD (mol/&#x003bc;g protein)</td><td>4.22&#x02009;&#x000b1;&#x02009;0.48</td><td>4.37&#x02009;&#x000b1;&#x02009;0.49</td><td>3.6</td><td>0.827</td></tr><tr><td>Muscle citrate synthase (mol/&#x003bc;g protein)</td><td>0.66&#x02009;&#x000b1;&#x02009;0.05</td><td>0.75&#x02009;&#x000b1;&#x02009;0.05</td><td>13.6</td><td>0.262</td></tr><tr><td>Muscle cytochrome <italic>c</italic> oxidase (mol/&#x003bc;g protein)</td><td>1.48&#x02009;&#x000b1;&#x02009;0.12</td><td>1.67&#x02009;&#x000b1;&#x02009;0.12</td><td>12.8</td><td>0.262</td></tr><tr><td colspan="5">Intramyocellular triacylglycerols (AU)</td></tr><tr><td>&#x000a0;Type 1</td><td>0.027&#x02009;&#x000b1;&#x02009;0.004</td><td>0.022&#x02009;&#x000b1;&#x02009;0.004</td><td>&#x02212;18.5</td><td>0.339</td></tr><tr><td>&#x000a0;Type 2</td><td>0.010&#x02009;&#x000b1;&#x02009;0.002</td><td>0.008&#x02009;&#x000b1;&#x02009;0.002</td><td>&#x02212;20.0</td><td>0.489</td></tr><tr><td>&#x000a0;Mixed</td><td>0.019&#x02009;&#x000b1;&#x02009;0.003</td><td>0.016&#x02009;&#x000b1;&#x02009;0.002</td><td>&#x02212;15.8 </td><td>0.429</td></tr><tr><td colspan="5">Succinate dehydrogenase activity (AU)</td></tr><tr><td>&#x000a0;Type 1</td><td>0.084&#x02009;&#x000b1;&#x02009;0.005</td><td>0.075&#x02009;&#x000b1;&#x02009;0.004</td><td>&#x02212;10.7</td><td>0.122</td></tr><tr><td>&#x000a0;Type 2</td><td>0.057&#x02009;&#x000b1;&#x02009;0.003</td><td>0.052&#x02009;&#x000b1;&#x02009;0.003</td><td>&#x02212;8.8</td><td>0.221</td></tr><tr><td>&#x000a0;Mixed</td><td>0.073&#x02009;&#x000b1;&#x02009;0.003</td><td>0.062&#x02009;&#x000b1;&#x02009;0.003</td><td>&#x02212;15.1</td><td>0.028</td></tr></tbody></table><table-wrap-foot><p>Data are presented as means&#x000b1;SEM or %</p><p><italic>AU</italic> Arbitrary units</p><p><sup>a</sup>Insulin sensitivity according to Matsuda and DeFronzo [<xref ref-type="bibr" rid="CR15">15</xref>]</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Insulin sensitivity index, adiponectin oligomer concentrations, HbA<sub>1c</sub> and enzyme activities (means&#x000b1;SEM) after 4&#x000a0;weeks of consumption of whisky or water in lean and overweight subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#x000a0;</th><th colspan="4">Lean group</th><th colspan="4">Overweight group</th></tr><tr><th>Water</th><th>Whisky</th><th>% Change</th><th><italic>p</italic> value</th><th>Water</th><th>Whisky</th><th>% Change</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Insulin sensitivity index<sup>a</sup></td><td>13.3&#x02009;&#x000b1;&#x02009;1.9</td><td>13.0&#x02009;&#x000b1;&#x02009;1.9</td><td>&#x02212;2.3</td><td>0.93</td><td>7.8&#x02009;&#x000b1;&#x02009;1.6</td><td>4.6&#x02009;&#x000b1;&#x02009;1.6</td><td>&#x02212;41.0 </td><td>0.21</td></tr><tr><td>Adiponectin (mg/l)</td><td>8.1&#x02009;&#x000b1;&#x02009;0.3</td><td>9.4&#x02009;&#x000b1;&#x02009;0.3</td><td>16.1</td><td>0.01</td><td>7.7&#x02009;&#x000b1;&#x02009;0.2</td><td>8.5&#x02009;&#x000b1;&#x02009;0.2</td><td>10.4</td><td>0.08</td></tr><tr><td>&#x000a0;HMW</td><td>0.8&#x02009;&#x000b1;&#x02009;1.2</td><td>1.2&#x02009;&#x000b1;&#x02009;0.2</td><td>50.0</td><td>0.12</td><td>0.8&#x02009;&#x000b1;&#x02009;0.1</td><td>0.8&#x02009;&#x000b1;&#x02009;0.1</td><td>0</td><td>0.62</td></tr><tr><td>&#x000a0;MMW</td><td>4.2&#x02009;&#x000b1;&#x02009;0.3</td><td>4.8&#x02009;&#x000b1;&#x02009;0.3</td><td>14.3</td><td>0.13</td><td>3.9&#x02009;&#x000b1;&#x02009;0.2</td><td>4.1&#x02009;&#x000b1;&#x02009;0.2</td><td>5.1</td><td>0.52</td></tr><tr><td>&#x000a0;LMW</td><td>3.2&#x02009;&#x000b1;&#x02009;0.4</td><td>3.4&#x02009;&#x000b1;&#x02009;0.4</td><td>6.3</td><td>0.69</td><td>3.1&#x02009;&#x000b1;&#x02009;0.4</td><td>3.5&#x02009;&#x000b1;&#x02009;0.4</td><td>12.9</td><td>0.50</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>4.9&#x02009;&#x000b1;&#x02009;0.02</td><td>4.8&#x02009;&#x000b1;&#x02009;0.02</td><td>&#x02212;2.0</td><td>0.04</td><td>4.9&#x02009;&#x000b1;&#x02009;0.02</td><td>4.9&#x02009;&#x000b1;&#x02009;0.02</td><td>0</td><td>0.53</td></tr><tr><td>Muscle &#x003b2;-HAD (mol/&#x003bc;g protein)</td><td>4.67&#x02009;&#x000b1;&#x02009;0.50</td><td>5.10&#x02009;&#x000b1;&#x02009;0.45</td><td>9.2</td><td>0.55</td><td>3.46&#x02009;&#x000b1;&#x02009;0.90</td><td>3.69&#x02009;&#x000b1;&#x02009;1.01</td><td>6.7</td><td>0.87</td></tr><tr><td>Muscle citrate synthase (mol/&#x003bc;g protein)</td><td>0.73&#x02009;&#x000b1;&#x02009;0.08</td><td>0.92&#x02009;&#x000b1;&#x02009;0.07</td><td>26.0</td><td>0.11</td><td>0.60&#x02009;&#x000b1;&#x02009;0.05</td><td>0.54&#x02009;&#x000b1;&#x02009;0.06</td><td>&#x02212;10.0</td><td>0.51</td></tr><tr><td>Muscle cytochrome <italic>c</italic> oxidase (mol/&#x003bc;g protein)</td><td>1.72&#x02009;&#x000b1;&#x02009;0.15</td><td>2.12&#x02009;&#x000b1;&#x02009;0.14</td><td>23.3</td><td>0.08</td><td>1.33&#x02009;&#x000b1;&#x02009;0.13</td><td>1.13&#x02009;&#x000b1;&#x02009;0.15</td><td>&#x02212;15.0</td><td>0.36</td></tr><tr><td colspan="9">Intramyocellular triacylglycerols (AU)</td></tr><tr><td>&#x000a0;Type 1</td><td>0.022&#x02009;&#x000b1;&#x02009;0.006</td><td>0.016&#x02009;&#x000b1;&#x02009;0.005</td><td>&#x02212;27.3</td><td>0.50</td><td>0.032&#x02009;&#x000b1;&#x02009;0.006</td><td>0.028&#x02009;&#x000b1;&#x02009;0.006</td><td>&#x02212;12.5</td><td>0.61</td></tr><tr><td>&#x000a0;Type 2</td><td>0.006&#x02009;&#x000b1;&#x02009;0.002</td><td>0.008&#x02009;&#x000b1;&#x02009;0.002</td><td>33.3</td><td>0.41</td><td>0.013&#x02009;&#x000b1;&#x02009;0.003</td><td>0.007&#x02009;&#x000b1;&#x02009;0.003</td><td>&#x02212;46.2</td><td>0.14</td></tr><tr><td>&#x000a0;Mixed</td><td>0.014&#x02009;&#x000b1;&#x02009;0.004</td><td>0.013&#x02009;&#x000b1;&#x02009;0.003</td><td>&#x02212;7.1</td><td>0.86</td><td>0.024&#x02009;&#x000b1;&#x02009;0.004</td><td>0.019&#x02009;&#x000b1;&#x02009;0.004</td><td>&#x02212;20.8</td><td>0.40</td></tr><tr><td colspan="9">Succinate dehydrogenase activity (AU)</td></tr><tr><td>&#x000a0;Type 1</td><td>0.086&#x02009;&#x000b1;&#x02009;0.005</td><td>0.080&#x02009;&#x000b1;&#x02009;0.005</td><td>&#x02212;7.0</td><td>0.40</td><td>0.084&#x02009;&#x000b1;&#x02009;0.009</td><td>0.069&#x02009;&#x000b1;&#x02009;0.008</td><td>&#x02212;17.9</td><td>0.29</td></tr><tr><td>&#x000a0;Type 2</td><td>0.060&#x02009;&#x000b1;&#x02009;0.005</td><td>0.055&#x02009;&#x000b1;&#x02009;0.005</td><td>&#x02212;8.3</td><td>0.50</td><td>0.054&#x02009;&#x000b1;&#x02009;0.005</td><td>0.048&#x02009;&#x000b1;&#x02009;0.004</td><td>&#x02212;11.1</td><td>0.34</td></tr><tr><td>&#x000a0;Mixed</td><td>0.076&#x02009;&#x000b1;&#x02009;0.005</td><td>0.066&#x02009;&#x000b1;&#x02009;0.005</td><td>&#x02212;13.2</td><td>0.16</td><td>0.069&#x02009;&#x000b1;&#x02009;0.005</td><td>0.057&#x02009;&#x000b1;&#x02009;0.004</td><td>&#x02212;17.4</td><td>0.15</td></tr></tbody></table><table-wrap-foot><p>Data are presented as means&#x000b1;SEM or %</p><p><italic>AU</italic> Arbitrary units</p><p><sup>a</sup>Insulin sensitivity according to Matsuda and DeFronzo [<xref ref-type="bibr" rid="CR15">15</xref>]</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>This study showed that moderate alcohol consumption increases adiponectin concentrations, consistent with previous reports [<xref ref-type="bibr" rid="CR2">2</xref>]. We have now observed that the alcohol-induced increase of adiponectin may be oligomer specific. Moderate alcohol consumption increased particularly HMW adiponectin, MMW adiponectin to a lesser extent, but not LMW adiponectin. These results are in line with those of Bobbert et al. [<xref ref-type="bibr" rid="CR9">9</xref>] showing a similar pattern of changes in adiponectin oligomers after moderate weight reduction. Studies with thiazolidinedione or rigorous weight reduction show similar, but more pronounced results [<xref ref-type="bibr" rid="CR10">10</xref>]. HDL-cholesterol concentrations correlated particularly with HMW adiponectin, as previously shown [<xref ref-type="bibr" rid="CR9">9</xref>]. We have now also observed that HMW and MMW adiponectin are correlated with markers of muscle oxidative capacity, in line with reports of increased fat oxidation after adiponectin infusion [<xref ref-type="bibr" rid="CR3">3</xref>] and a recent study showing that adiponectin increases muscle oxidative capacity [<xref ref-type="bibr" rid="CR11">11</xref>]. Our results tend to confirm these findings and show that these relationships may be specific to HMW adiponectin. Altogether, this could provide an underlying mechanism for the proposed importance of HMW adiponectin in the aetiology of insulin resistance [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Despite this, the alcohol-induced increase of adiponectin and specifically HMW adiponectin did not affect muscle oxidative capacity, IMTG content and insulin sensitivity. As some subtle differences were present, we cannot completely rule out the hypothesis that changes in IMTG content and/or oxidative capacity could occur. Although it did not reach significance, we observed a 15&#x02013;20% lower IMTG content after whisky than water consumption, which is of similar magnitude to that observed for a weight loss and physical activity intervention [<xref ref-type="bibr" rid="CR12">12</xref>]. Furthermore, moderate alcohol consumption tended to increase muscle citrate synthase activity among lean men, but succinate dehydrogenase activity declined after moderate alcohol consumption in mixed muscle fibres. All citric acid cycle and respiratory chain enzymes are thought to change in parallel to perturbation [<xref ref-type="bibr" rid="CR13">13</xref>]. Our findings with citrate synthase and succinate dehydrogenase, however, are contradictory to this notion. This could simply be due to the measurement of ex vivo oxidative capacity or to chance. Alternatively, moderate alcohol consumption could differentially affect various enzymes in oxidative pathways such as the citric acid or glyoxylate cycle as suggested by Kokavec and Crowe [<xref ref-type="bibr" rid="CR14">14</xref>]. Because acetyl-CoA from ethanol oxidation is generated independently from activation of pyruvate dehydrogenase complex, it may not affect the citric acid cycle. Alcohol may instead affect the glyoxylate cycle that bypasses part of the citric acid cycle, including succinate dehydrogenase [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Strengths of this study are its randomised, controlled crossover design. We assessed compliance to study treatments several times throughout the study and observed no significant deviations. It is therefore unlikely that our results are confounded by diet or lifestyle. Our study was, however, limited by a slightly small sample size for certain contrasts such as analyses in subgroups of lean and overweight men or of IMTG content. Therefore these results may be somewhat preliminary and need to be confirmed with larger sample sizes. Second, because insulin sensitivity was not the primary endpoint of this study, an OGTT was used to assess insulin sensitivity. However, we used an insulin sensitivity index that correlates well with the gold standard, the hyperinsulinaemic&#x02013;euglycaemic clamp technique [<xref ref-type="bibr" rid="CR15">15</xref>]. In addition, our results on insulin sensitivity do not differ from our previous studies using the clamp technique [<xref ref-type="bibr" rid="CR2">2</xref>]. We therefore believe that using this insulin sensitivity index has not influenced our results to a large extent.</p><p>In conclusion, this study shows that 4&#x000a0;weeks of daily moderate alcohol consumption increases adiponectin concentrations and particularly HMW adiponectin concentrations, but does not affect insulin sensitivity and oxidative capacity. Concentrations of HMW and MMW adiponectin were positively associated with muscle oxidative capacity.</p></sec></body><back><ack><title>Acknowledgements</title><p>The skilful help of R. Koopman, M. Brouwers and A. Georgieva is gratefully acknowledged. We thank the volunteers for their enthusiastic participation. The research described in this paper was funded by the Dutch Foundation for Alcohol Research.</p><p><bold>Duality of interest</bold> The authors have no duality of interest.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koppes</surname><given-names>LL</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name></person-group><article-title>Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.3.719</pub-id></citation><citation citation-type="display-unstructured">Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ (2005) Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 28:719&#x02013;725 <pub-id pub-id-type="pmid">15735217</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sierksma</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Ouchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.1.184</pub-id></citation><citation citation-type="display-unstructured">Sierksma A, Patel H, Ouchi N et al (2004) Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 27:184&#x02013;189 <pub-id pub-id-type="pmid">14693987</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Waki</surname><given-names>H</given-names></name><etal/></person-group><article-title>The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/90984</pub-id></citation><citation citation-type="display-unstructured">Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941&#x02013;946 <pub-id pub-id-type="pmid">11479627</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Horikoshi</surname><given-names>M</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.2337/dc05-1801</pub-id></citation><citation citation-type="display-unstructured">Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357&#x02013;1362 <pub-id pub-id-type="pmid">16732021</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siler</surname><given-names>SQ</given-names></name><name><surname>Neese</surname><given-names>RA</given-names></name><name><surname>Hellerstein</surname><given-names>MK</given-names></name></person-group><article-title>De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>70</volume><fpage>928</fpage><lpage>936</lpage></citation><citation citation-type="display-unstructured">Siler SQ, Neese RA, Hellerstein MK (1999) De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr 70:928&#x02013;936 <pub-id pub-id-type="pmid">10539756</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Passonneau</surname><given-names>JV</given-names></name></person-group><source>A flexible system of enzymatic analysis</source><year>1972</year><publisher-loc>New York</publisher-loc><publisher-name>Academic</publisher-name></citation><citation citation-type="display-unstructured">Lowry OH, Passonneau JV (1972) A flexible system of enzymatic analysis. Academic, New York </citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname><given-names>R</given-names></name><name><surname>Schaart</surname><given-names>G</given-names></name><name><surname>Hesselink</surname><given-names>MK</given-names></name></person-group><article-title>Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids</article-title><source>Histochem Cell Biol</source><year>2001</year><volume>116</volume><fpage>63</fpage><lpage>68</lpage></citation><citation citation-type="display-unstructured">Koopman R, Schaart G, Hesselink MK (2001) Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol 116:63&#x02013;68 <pub-id pub-id-type="pmid">11479724</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gosker</surname><given-names>HR</given-names></name><name><surname>Mameren</surname><given-names>H</given-names></name><name><surname>Dijk</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1183/09031936.02.00762001</pub-id></citation><citation citation-type="display-unstructured">Gosker HR, van Mameren H, van Dijk PJ et al (2002) Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 19:617&#x02013;625 <pub-id pub-id-type="pmid">11998989</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bobbert</surname><given-names>T</given-names></name><name><surname>Rochlitz</surname><given-names>H</given-names></name><name><surname>Wegewitz</surname><given-names>U</given-names></name><etal/></person-group><article-title>Changes of adiponectin oligomer composition by moderate weight reduction</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2712</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.9.2712</pub-id></citation><citation citation-type="display-unstructured">Bobbert T, Rochlitz H, Wegewitz U et al (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712&#x02013;2719 <pub-id pub-id-type="pmid">16123361</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pajvani</surname><given-names>UB</given-names></name><name><surname>Hawkins</surname><given-names>M</given-names></name><name><surname>Combs</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>12152</fpage><lpage>12162</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311113200</pub-id></citation><citation citation-type="display-unstructured">Pajvani UB, Hawkins M, Combs TP et al (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152&#x02013;12162 <pub-id pub-id-type="pmid">14699128</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Civitarese</surname><given-names>AE</given-names></name><name><surname>Ukropcova</surname><given-names>B</given-names></name><name><surname>Carling</surname><given-names>S</given-names></name><etal/></person-group><article-title>Role of adiponectin in human skeletal muscle bioenergetics</article-title><source>Cell Metab</source><year>2006</year><volume>4</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2006.05.002</pub-id></citation><citation citation-type="display-unstructured">Civitarese AE, Ukropcova B, Carling S et al (2006) Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4:75&#x02013;87 <pub-id pub-id-type="pmid">16814734</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Kelley</surname><given-names>DE</given-names></name></person-group><article-title>Effects of weight loss and physical activity on muscle lipid content and droplet size</article-title><source>Obes Res</source><year>2004</year><volume>12</volume><fpage>761</fpage><lpage>769</lpage></citation><citation citation-type="display-unstructured">He J, Goodpaster BH, Kelley DE (2004) Effects of weight loss and physical activity on muscle lipid content and droplet size. Obes Res 12:761&#x02013;769 <pub-id pub-id-type="pmid">15166296</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Stryer</surname><given-names>L</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Stryer</surname><given-names>L</given-names></name></person-group><article-title>Citric acid cycle</article-title><source>Biochemistry</source><year>1988</year><edition>3</edition><publisher-loc>New York</publisher-loc><publisher-name>Freeman</publisher-name><fpage>373</fpage><lpage>396</lpage></citation><citation citation-type="display-unstructured">Stryer L (1988) Citric acid cycle. In: Stryer L (ed.) Biochemistry, 3rd edn. Freeman, New York, pp 373&#x02013;396 </citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kokavec</surname><given-names>A</given-names></name><name><surname>Crowe</surname><given-names>SF</given-names></name></person-group><article-title>Alcohol consumption in the absence of adequate nutrition may lead to activation of the glyoxylate cycle in man</article-title><source>Med Hypotheses</source><year>2002</year><volume>58</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1054/mehy.2001.1524</pub-id></citation><citation citation-type="display-unstructured">Kokavec A, Crowe SF (2002) Alcohol consumption in the absence of adequate nutrition may lead to activation of the glyoxylate cycle in man. Med Hypotheses 58:411&#x02013;415 <pub-id pub-id-type="pmid">12056879</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><article-title>Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><fpage>1462</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.9.1462</pub-id></citation><citation citation-type="display-unstructured">Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462&#x02013;1470 <pub-id pub-id-type="pmid">10480510</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>&#x003b2;-HAD</term><def><p>&#x003b2;-3-hydroxyacyl coenzyme A dehydrogenase</p></def></def-item><def-item><term>HMW</term><def><p>high molecular weight</p></def></def-item><def-item><term>IMTG</term><def><p>intramyocellular triacylglycerol</p></def></def-item><def-item><term>LMW</term><def><p>low molecular weight</p></def></def-item><def-item><term>MMW</term><def><p>medium molecular weight</p></def></def-item></def-list></glossary></back></article>


